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Background: Members of the Rho family of small GTP-binding proteins, such
as Rho, Rac and Cdc42, have a role in a wide range of cell responses. These
proteins function as molecular switches by virtue of a conformational change
between the GTP-bound (active) and GDP-bound (inactive) forms. In addition,
most members of the Rho and Rac subfamilies cycle between the cytosol and
membrane. The cytosolic guanine nucleotide dissociation inhibitors, RhoGDIs,
regulate both the GDP/GTP exchange cycle and the membrane
association/dissociation cycle.
Results: We have used NMR spectroscopy and site-directed mutagenesis to
identify the regions of human RhoGDI-1 that are involved in binding Rac-1. The
results emphasise the importance of the flexible regions of both proteins in the
interaction. At least one specific region (residues 46–57) of the flexible
N-terminal domain of RhoGDI, which has a tendency to form an amphipathic
helix in the free protein, makes a major contribution to the binding energy of the
complex. In addition, the primary site of Rac-1 binding on the folded domain of
RhoGDI involves the β4–β5 and β6–β7 loops, with a slight movement of the
310 helix accompanying the interaction. This binding site is on the same face of
the protein as the binding site for the isoprenyl group of post-translationally
modified Rac-1, but is distinct from this site.
Conclusions: Isoprenylated Rac-1 appears to interact with three distinct sites
on RhoGDI. The isoprenyl group attached to the C terminus of Rac-1 binds in a
pocket in the folded domain of RhoGDI. This is distinct from the major site on
this domain occupied by Rac-1 itself, which involves two loops at the opposite
end to the isoprenyl-binding site. It is probable that the flexible C-terminal region
of Rac-1 extends from the site at which Rac-1 contacts the folded domain of
RhoGDI to allow the isoprenyl group to bind in the pocket at the other end of
the RhoGDI molecule. Finally, the flexible N terminus of RhoGDI-1, and
particularly residues 48–58, makes a specific interaction with Rac-1 which
contributes substantially to the binding affinity. 
Introduction
The Rho family of small GTP-binding proteins includes
the isoforms of Rho, Rac, Cdc42 and TC10 [1,2] which
have roles in a variety of processes: regulation of the actin
cytoskeleton in response to external stimuli; activation of
MAP kinase cascades; cell transformation by Ras; cell-
cycle progression; and the activation of NADPH oxidase
[2–9]. The cycling of these proteins between the GTP-
bound and GDP-bound forms is controlled by guanine
nucleotide exchange factors (GEFs), which catalyse the
exchange of GTP for GDP, and the GTPase-activating
protein (GAPs), which accelerate GTP hydrolysis [1,2]. In
addition, their activity is regulated by the RhoGDIs
[10,11], which inhibit release of nucleotides from the
GTPase [11,12] and also control partitioning of the
GTPase between the cytosol and membrane [13–15].
Three human RhoGDIs have been identified. The ubiq-
uitously expressed RhoGDI-1 [11], the form studied here,
and D4/Lys-GDI (RhoGDI-2) [16,17], expressed in
haematopoetic cells, both have a broad range of activity
towards the Rho proteins. In contrast, RhoGDI-3 [18] is
specific for RhoB and RhoG, and unlike the other two
cytoplasmic forms is associated with the membrane or pos-
sibly the cytoskeleton. Although the binding of a Rho
family GTPase to RhoGDI appears to lock it into its inac-
tive state, in some cases (e.g. in the regulation of
ezrin/radixin/moesin [19] and phospholipase Cβ2 [20]) the
GTPase has been reported to bind to an effector molecule
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as a complex with RhoGDI, suggesting that RhoGDI may
also have a role in directing the GTPase to the effector. 
We have recently determined the structure of human
RhoGDI-1 by a combination of nuclear magnetic reso-
nance (NMR) spectroscopy and crystallography [21]. The
15N–1H HSQC spectrum of full-length RhoGDI-1
showed two types of cross-peaks: between 50 and 60 of
the backbone amide cross-peaks had much narrower
linewidths than the others. These sharp cross-peaks were
removed by selective cleavage with trypsin at Arg58. This
indicated that RhoGDI consists of two domains — a flexi-
ble N-terminal domain of about 60 amino acids and a
folded domain. Similar observations have been made with
a fragment of  bovine RhoGDI comprising residues 23 to
204 — RhoGDI(23–204) [22]. The crystal structure [21]
of human RhoGDI(59–204) and the solution structure
[22] of bovine RhoGDI(60–204) showed that the trun-
cated form has an immunoglobulin fold. We now report
the use of the assigned 1H, 13C and 15N resonances of
human RhoGDI-1 to identify the residues that are
involved in its interaction with Rac-1.
Results and discussion
The flexible N-terminal domain of RhoGDI
Figure 1a shows the 1H–15N correlation spectrum of
human RhoGDI(59–204), uniformly labelled with 15N.
The backbone resonances were assigned using two sepa-
rate samples, one of the truncated (59–204) protein and
the other of the full-length protein. The tendency of the
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Figure 1
NMR data of RhoGDI-1. (a) A 1H–15N
correlation spectrum of uniformly
[13C,15N]-labelled RhoGDI-1, with resonance
assignments indicated. (b) Secondary
structure of RhoGDI-1 as identified from the
NMR data. From bottom to top: the amino
acid sequence of RhoGDI-1; sequential and
intraresidue NOEs (the heights of the solid
bars are proportional to the intensities of the
NOE cross-peaks; asterisks indicate NOEs
that have not been identified due to
resonance overlap and/or missing
assignments); the consensus chemical-shift
index; and the secondary structure in the
X-ray structure (double lines indicate β
strands and helical symbols indicate the 310
helix). The sequence in the N-terminal domain
identified by NMR as having a tendency to
form a helix is indicated by a zig-zag line.
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full-length protein to cleave meant that this latter sample
was used to obtain the assignments of the N-terminal
domain only; the high intensities of the resonances from
the flexible domain allowed data acquisition for this
domain to be completed more quickly than for the folded
domain. The resonances were assigned on 13C,15N-labelled
samples using a suite of triple-resonance experiments as
described in the Materials and methods section; we
showed earlier that the signals of the folded domain were
virtually unaffected by removal of the flexible N-terminal
domain [21]. The information on the secondary structure
in the N-terminal domain was derived from the intra-
residue and sequential nuclear Overhauser effects (NOEs)
involving backbone amide protons and from the carbon
chemical-shift index [23], as shown schematically in
Figure 1b. For the folded domain, the secondary structure
deduced from the NMR data is in good agreement with
the nine β strands and a short 310 helix identified in our 
X-ray crystal structure of human RhoGDI(59–204) [21]
and with the solution structure of bovine RhoGDI(60–204)
[22], which differs from the human protein in only six
amino acid substitutions; there are only minor differences
(plus or minus two residues) between the structures at the
start and end points of some of the β strands. 
Most of the N-terminal domain has a flexible random-coil
structure, as indicated by the observed chemical shifts and
NOEs as well as the narrow linewidths. However, a short
stretch of this domain, residues 48–58, shows a pattern of
sequential and intraresidue NOEs characteristic of a
helical structure (Figure 1b); no medium-range NOEs
characteristic of a helical fold were observed, and we con-
clude that this part of the sequence has a tendency to form
a helix, but exists in solution in equilibrium between
helical and random-coil conformations. 
The binding site for the GTPase isoprenyl group
The enzyme geranylgeranyl transferase I recognises the
C-terminal Cys-X-X-Leu sequence of the Rho family
GTPases and transfers a geranylgeranyl group to the cys-
teine residue. This isoprenylation of the GTPase is
important for tight binding to RhoGDI [24]. Examination
of the structure of the folded domain of RhoGDI revealed
the existence of a largely hydrophobic cavity between the
two β sheets of the immunoglobulin fold [21,22], which
was proposed to be the binding site for this isoprenyl
group. Clear evidence for this was reported [22], which
showed that the chemical shifts of the resonances of a
number of residues in and near this cavity in bovine
RhoGDI(60–204) were affected by addition of a farnesy-
lated peptide. We have carried out similar experiments
with human RhoGDI, using N-acetyl farnesyl cysteine.
The addition of 0.2–1 M equivalents (100–500 µM) of
N-acetyl farnesyl cysteine to either the truncated or intact
human RhoGDI produces a limited number of clear
changes (greater than the linewidth of the cross-peak) in
the 15N and/or 1H chemical shifts of specific residues. Pro-
gressive changes in chemical shift were observed on titra-
tion of the ligand into the protein sample (data not
shown), implying that the free and complexed proteins
are in fast exchange on the NMR timescale, and allowing
the assignment of the protein resonances in the complex
to be obtained from the assignments of the free protein.
Addition of an excess of N-acetyl S-farnesyl cysteine or of
even small amounts of N-acetyl S-geranylgeranyl cysteine
resulted in general nonspecific line-broadening of the
RhoGDI signals, presumably due to a detergent-like
action. However, the specific changes in chemical shift
seen at low concentrations of N-acetyl S-farnesyl cysteine
reflect direct protein–ligand contacts and/or small changes
in conformation on complex formation. 
In the full-length RhoGDI(1–204), the chemical-shift
changes on addition of N-acetyl farnesyl cysteine occur
only in the resonances of residues arising from the folded
part of the molecule; none of the intense signals from the
flexible N-terminal region is affected. The changes seen
with the full-length protein are identical to those seen on
adding N-acetyl farnesyl cysteine to the truncated form,
RhoGDI(59–204), and include the backbone amide reso-
nances of 19 residues: Ser81, Leu104, Lys105, Val108,
Arg111, Gln130, His131, Tyr133, Glu163, Glu164, Ala165,
Lys167, Gly168, Met169, Ala171, Gly173, Ser174, Tyr175
and Lys178 (Figure 2). The list of affected residues is
closely similar (but not wholly identical) to that reported
[22] for the binding of a farnesylated peptide to the bovine
protein. These residues are clustered around the cavity
between the β sheets (Figure 3), and include six residues
previously identified [21] as lining the cavity. Of the 19
residues affected in human RhoGDI-1, 12 are surface
residues and seven are largely or completely buried. The
fact that some buried residues are affected indicates that
the chemical-shift changes cannot arise exclusively from
direct effects of ligand binding, but must also reflect some
degree of structural change. The surface residues affected
comprise largely residues in the loops between β strands 3
and 4 (residues 105–111) and between β strands 7 and 8
(residues 160–172); some movement of these loops on
ligand binding could account for the effects on buried
residues and on four residues on the opposite face of the
protein, Gly173 and Ser174 in β strand 8 and His131 and
Tyr133 in the neighbouring β strand 5. The residues
affected are predominantly uncharged; Figure 3a shows
that the patch of affected residues includes a nonpolar
surface patch at the C-terminal end of the molecule that is
connected to the cavity. 
The NMR evidence thus clearly defines the location of
the binding site for N-acetyl farnesyl cysteine, and sug-
gests that the cavity in RhoGDI and the neighbouring
hydrophobic surface patch form the site of interaction of
the C-terminal isoprenyl group of Rac, an interaction
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which makes an important contribution to the tight
binding of the two proteins to one another.
Residues affected by the binding of Rac-1
We showed earlier that the addition of recombinant non-
isoprenylated full-length Rac-1 to 15N-labelled full-
length RhoGDI-1 leads to specific changes in the
chemical shift of a limited number of cross-peaks in the
15N–1H heteronuclear single quantum coherence (HSQC)
spectrum [21] showing that non-isoprenylated Rac-1
binds specifically to RhoGDI, although much more
weakly than the geranylgeranylated protein. When Rac-1
was added to truncated RhoGDI(59–204), the spectrum
of the latter was unaffected [21], demonstrating the
importance of the flexible N-terminal region of RhoGDI
in binding Rac-1. An identification of the binding site for
Cdc42 on bovine RhoGDI, at the opposite end of the
structured domain to the isoprenyl-binding pocket, has
previously been proposed [22]. This was based on the
effects of substoichiometric amounts of Cdc42 on the
intensities of cross-peaks, assumed to reflect linewidth
changes due to exchange broadening, in the 1H–15N
HSQC spectrum of RhoGDI(23–204). This approach to
mapping the interaction surface between the two proteins
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Figure 2
Amino acid sequence alignment for members
of the RhoGDI family. Residues identical in at
least five of the eight sequences are shown in
bold. Residues with amide resonances
affected by ligand binding are indicated in the
sequence of human RhoGDI-1: residues
affected by N-acetyl farnesyl cysteine binding
are shown in blue, residues affected by Rac-1
binding are in red, and residues affected by
both ligands are in green. Proline residues,
which do not have amide resonances, and
four residues for which amide resonances
have not been assigned are shown in italics.
The secondary structure elements in the
folded domain are indicated by β for β strands
and 3 for the 310 helix. The sequence
alignment was carried out using CLUSTAL W,
with a minor manual adjustment to avoid an
insertion in the 310 helix. The sequences
shown are: hRGDI-1, human RhoGDI-1;
bRGDI, bovine RhoGDI; hRGDI-2, human
RhoGDI-2 (equivalent to D4/Ly GDI);
mRGDI-2, mouse RhoGDI-2; hRGDI-3,
human RhoGDI-3 (equivalent to GDIγ);
mRGDI-3, mouse RhoGDI-3; cRGDI,
C. elegans RhoGDI homologue; yRGDI,
S. cerevisiae RhoGDI.
Figure 3
Molecular surface of the folded domain of
RhoGDI coloured to indicate residues with
backbone amide 1H and/or 15N resonances
that show significant changes in chemical
shift on ligand binding. (a) Residues affected
by binding N-acetyl S-farnesyl cysteine
(magenta). (b) Ribbon diagram of the
backbone of RhoGDI in the same orientation
as (a). (c,d) Residues affected by binding
Rac-1 (green). The view in (d) differs from
those in (a–c) by a 180° rotation about the
horizontal axis. (Parts (a), (c) and (d) were
created using the program GRASP [33].)
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has some disadvantages: it requires demonstration that
exchange between the complexed and free protein is rea-
sonably fast, and the origin of the line-broadening
(leading to loss of intensity) may be either or both a
decrease in mobility (in this case, notably in the N-termi-
nal domain) or exchange broadening associated with a
change in chemical shift.
We have now established conditions under which a reason-
ably stable stoichiometric complex between RhoGDI and
Rac-1 can be formed; exchange between the free and com-
plexed states is slow, permitting the direct observation of
the resonances of the complex. Using the tranverse relax-
ation-optimised spectroscopy (TROSY) technique [25], a
1H–15N correlation spectrum was obtained which con-
tained sharp resonances from this 46 kDa complex
(Figure 4). The stability of the complex is limited by a very
slow cleavage (over several days, presumably by very small
amounts of contaminating proteases) of full-length
RhoGDI in its N-terminal region; this is somewhat faster
in complexed than in free RhoGDI. This cleavage leads to
a dissociation of the complex, and the 15N–1H HSQC spec-
trum of cleaved RhoGDI liberated in this way is identical
to that of the free truncated protein. This confirms the
importance of the N-terminal domain for binding to Rac-1. 
In line with these observations, and in contrast to the
effects of N-acetyl farnesyl cysteine, the effects of Rac-1
binding involve resonances from both the flexible N-ter-
minal domain and the structured domain. The resonances
of RhoGDI in the complex are not yet assigned, so that
the magnitude of the shifts of individual resonances
cannot be accurately determined. We have used the
‘minimum chemical shift’ approach [26,27], in which the
chemical-shift difference from a given cross-peak in the
free protein to the closest cross-peak in the complex is cal-
culated, as described in the Materials and methods
section. This approach can provide a reliable identification
of the interaction site(s) [27,28], although caution is clearly
required in using it in very crowded regions of the spec-
trum; work is currently in progress to assign the reso-
nances of both RhoGDI-1 and Rac-1 in the complex.
Contacts in the folded domain
Of 134 residues in the folded domain, 49 residues
(70–204) of full-length RhoGDI-1 (36%) show changes in
backbone amide chemical shifts on Rac-1 binding which
are significant by the criterion described in the the Materi-
als and methods section. These residues are distributed
quite widely through the sequence (Figure 2) and on the
surface of the protein (Figure 3), but on detailed examina-
tion a pattern does emerge. On the same surface of the
molecule as the isoprenyl-binding pocket (Figure 3a), two
groups of residues affected by Rac-1 binding can be dis-
cerned: a small number of residues near the isoprenyl-
binding pocket and a much larger patch at the other end
of the domain. Of the 19 residues affected by N-acetyl far-
nesyl cysteine binding only four are also affected by Rac-1
binding (Figure 2). This suggests that the non-isopreny-
lated but full-length Rac-1 protein makes only minimal
contact with the part of RhoGDI which binds the iso-
prenyl group. Further evidence for this was obtained from
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Figure 4
Binding of RhoGDI-1 to Rac-1. 1H–15N
TROSY spectra of RhoGDI-1 alone
(0.25 mM; black) and in the presence of
Rac-1 (0.3 mM; red). 
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experiments in which the water-soluble nitroxide spin-
label TEMPO was added to a sample of the complex.
Marked line-broadening, indicative of accessibility to the
spin-label, was observed for residues surrounding the iso-
prenyl-binding cavity (data not shown).
The large distinct surface patch of residues affected by
Rac-1 binding at the other end of the folded domain from
the isoprenyl-binding pocket (Figure 3c) consists primarily
of residues in the loops between β strands 6 and 7
(residues 143–156) and between β strands 4 and 5
(residues 119–125); the latter stretch of residue forms an
extension across to the point where the flexible N termi-
nus enters the folded domain. It is notable that the
residues in these two surface loops are substantially con-
served in the sequences of all mammalian RhoGDIs and
to a lesser extent in those of the Caenorhabditis elegans and
Saccharomyces cerevisiae proteins (Figure 2); in the β6–β7
loop in particular, all but three of the 13 residues are
affected by Rac binding and all but two are conserved in at
least five of the RhoGDI sequences in Figure 2. We there-
fore conclude that these two loops form a primary site of
interaction of Rac-1 with the folded domain of RhoGDI-1. 
Gosser et al., [22] also identified these loops as being
affected by Cdc42 binding to bovine RhoGDI, but
reported a much larger patch of affected residues, includ-
ing residues in the β8–β9 loop (181–189). Although we see
changes in β strand 9, primarily in buried residues (see
below), only two residues in the preceding loop (Thr187
and Asp188) are affected in our experiments, and these
are on the opposite face of the molecule. It remains to be
established whether this difference represents a real dif-
ference in the mode of binding of Cdc42 and Rac-1 to
RhoGDI, or only reflects the methods used. For example,
line-broadening of these residues could arise from a
decrease in mobility of this loop rather than from large
chemical-shift changes.
Apart from the residues in this major patch (Figure 3c), a
number of buried residues and residues on the opposite
face of the protein (Figure 3d) are also affected by Rac-1
binding. The affected surface residues shown in Figure
3d fall into two groups. Firstly, some residues in the
β4–β5 and β6–β7 loops discussed above, together with
two residues in the β8–β9 loop, surround the point at
which the flexible N-terminal domain joins the folded
domain. Secondly, a number of surface residues in
contact with the short 310 helix are affected. It is notable
that several residues in β strand 9 (residues 193–199) are
also affected by Rac-1 binding; these residues are buried
in the RhoGDI structure and lie beneath the 310 helix. In
order to establish whether the effects of Rac-1 binding on
this part of the molecule are direct or indirect, we con-
structed a mutant of RhoGDI-1 in which Asp93 and
Glu95 were replaced by asparagine and glutamine,
respectively. These two residues are located near the 
N-terminal end of the 310 helix, in a region where several
surface residues are affected by Rac-1 binding. However,
the double mutant RhoGDI D93N/E95Q showed an
affinity for N-methylanthraniloyl GDP (mantGDP)–Rac-1
indistinguishable from that of the wild-type protein.
These observations suggest that the primary Rac-1
binding site on the folded domain of RhoGDI involves
the β4–β5 and β6–β7 loops, and that some degree of
structural change, perhaps involving a slight movement of
the 310 helix, accompanies the interaction.
Interaction of Rac-1 with the flexible N-terminal domain
On addition of Rac-1 to RhoGDI-1, almost half the sharp
amide resonances arising from the N-terminal domain
show significant changes in chemical shift (Figure 4).
With very few exceptions, however, (see below) they
remain markedly sharper than resonances from the
folded domain, demonstrating that most of the N-termi-
nal ~70 residues retain substantial mobility in the
complex. The first 22–25 residues of RhoGDI are not
required for binding Cdc42 [22,29], although similar data
for Rac binding have not previously been reported and
there is little sequence conservation among these
residues; nonetheless, several residues show significant
changes in chemical shift. This suggests the possibility of
a weak interaction between these residues and Rac-1,
most probably with a rapid equilibrium between confor-
mations in which some of the first 25 residues of
RhoGDI make contact with Rac-1 and conformations in
which they do not.
There are clear-cut effects of Rac-1 binding on two
regions of the N-terminal domain of RhoGDI (Figure 2),
residues 22–41 and 45–60. In the first of these regions, 17
residues changes in amide chemical shift (discounting two
proline residues). This part of the sequence shows a mod-
erate degree of conservation, 47% of the residues being
conserved in at least five of the sequences in Figure 2. In
the second region, residues 45–60, 14 residues show
changes in chemical shift; there is greater conservation in
this region with 73% of the residues being identical in at
least five RhoGDI sequences. In addition, marked line-
broadening effects are seen in the spectrum of the
selectively 15N-leucine-labelled protein for the amide res-
onances of Leu48, Leu55 and Leu56, but not, for
example, for Leu41. Similar broadening is seen for the res-
onance of Gly57, which is well resolved in the spectrum of
the uniformly labelled protein. This combination of shifts
and line-broadening clearly suggests that this part of the
N-terminal domain interacts strongly with Rac-1. It is
notable that this region includes residues 48–58, which
show a tendency to form a helix in free RhoGDI-1. In con-
trast, no NOEs suggestive of any nascent secondary struc-
ture were observed for residues 22–41. Modelling the
putative helix for residues 48–58 shows that it would have
52 Structure 2000, Vol 8 No 1
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an amphipathic character with a nonpolar face containing
the conserved leucine residues that show clear line-broad-
ening, suggesting that this face of the helix might interact
with Rac-1. 
To investigate the importance of this possible interaction,
we constructed mutants in which Leu55 and Leu56 of
RhoGDI-1 were both replaced by the polar residues
serine and asparagine. Both L55S/L56S and L55N/L56N
Research Article  Mapping the Rac-1 binding site on RhoGDI-1 Lian et al. 53
Figure 5
Comparison of wild-type and mutant RhoGDI-
1 binding to Rac-1. (a) Fluorescence
emission spectrum of the mantGDP–Rac-1
complex (1 µM) alone, and in the presence of
wild-type RhoGDI-1 (12 µM) or L55S/L56S
RhoGDI-1 (12 µM). (b) Effects of RhoGDI-1
binding on the high-field methyl region of the
1H NMR spectra. The spectrum of a mixture
of wild-type RhoGDI-1 and Rac-1 (A) is
clearly different from the sum of the spectra of
the two individual proteins (B), showing that a
complex is formed. In contrast, for
L55S/L56S RhoGDI, the spectrum of the
mixture (C) is identical to the sum of the
individual spectra (D), showing that there is
no significant interaction.
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double mutants showed dramatically lower affinities than
wild-type RhoGDI-1 for Rac-1 (Figure 5). Wild-type
RhoGDI-1 bound to non-isoprenylated Rac-1 with a Kd of
1.66 (± 0.07) µM, but neither of the RhoGDI-1 mutants
quenched the fluorescence of mant-GDP–Rac-1
(Figure 5a). Furthermore, the NMR spectrum of a
mixture of Rac-1 with mutant RhoGDI-1 was simply the
sum of the spectrum of the two components (Figure 5b),
showing that they do not interact even at millimolar con-
centrations. The substitution of Leu55 and Leu56 in the
N-terminal domain with polar residues thus decreases the
affinity of RhoGDI-1 for Rac-1 by at least four orders of
magnitude. These results demonstrate that residues 46–58
form a primary site of interaction between RhoGDI-1 and
Rac-1. Residues 27–41 are clearly also affected by the
interaction, but the exact nature of their involvement in
complex formation is yet to be determined. 
Biological implications
Members of the Rho family of small GTPases are
involved in many cellular processes. In addition, the
GTPase Rac has a specific role in the activation of the
phagocytic NADPH oxidase. These small GTPases are
regulated by the cytosolic guanine nucleotide dissociation
inhibitors, RhoGDIs, in two ways: by inhibiting the dis-
sociation of nucleotides from the GTPase, and by regu-
lating its association with and dissociation from the
membrane.  
Our studies show that isoprenylated Rac-1 can interact
with three distinct sites on RhoGDI-1, implying that (at
least) three distinct sites on Rac-1 must be involved in
the interaction. The isoprenyl group on Rac-1 binds in a
hydrophobic pocket in the folded domain of RhoGDI-1,
which is distinct from the major site on this domain
occupied by Rac-1 itself. The N-terminal flexible region
of RhoGDI-1, in particular residues 48–58, makes a
major contribution to the binding energy of the complex,
possibly interacting with residues in the mobile switch
regions of Rac-1. The multiple binding regions fit a
model where Rac-1 and RhoGDI-1 can interact with
one another even when Rac-1 is bound to the mem-
brane. The initial binding of the N-terminal region of
RhoGDI-1 would be followed by a structural rearrange-
ment resulting in the release of Rac-1 from the mem-
brane, and the insertion of the isoprenyl group of Rac-1
into the hydrophobic pocket of RhoGDI-1. This mode of
binding enables RhoGDI-1 to play an important role in
the regulation of both the GDP/GTP exchange and the
membrane association/dissociation cycles. 
The importance of the N-terminal region for tight
binding to Rac-1 demonstrated here parallels observa-
tions with RhoGDI-2. In RhoGDI-2, cleavage by inter-
leukin-1β-converting enzyme effectively removes the
equivalent N-terminal region and the resulting protein is
unable to bind to Rho GTPases [30]. The present results
also emphasise the importance of the flexible regions of
the two proteins in the formation of a tightly bound
Rac–RhoGDI complex. 
Materials and methods
The cDNA coding for residues 59–204 of RhoGDI-1 was transferred
into the Nde I and Bam HI sites in the expression vector pET11a (Phar-
macia) and the construct transformed into Escherichia coli BL21(DE3).
The transformant was grown on a defined medium containing 4 g/L
glucose and 1 g/L ammonium chloride. [15N]-labelled and [13C,15N]-
labelled protein were prepared by using 99% [15N]-NH4Cl and 99%
[13C]-glucose (both from Isotec Inc.) as appropriate; for [2H,15N]-
labelled protein, cells were grown in minimal media in 2H2O. The
protein was purified using a Pharmacia SP Sepharose cation exchange
column, eluting with a linear gradient of 0–1 M NaCl in buffer A
(50 mM sodium phosphate, 1 mM EDTA, 1 mM dithiothreitol [DTT]
pH 5.8). The protein was further purified by size-exclusion chromatog-
raphy using a Pharmacia Superdex 75 column in buffer A. Fractions
containing pure truncated RhoGDI-1 were pooled and concentrated
using an Amicon stirred cell. The protein was found to be homoge-
neous, as judged by sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS–PAGE), N-terminal sequencing and mass spec-
trometric analysis; the latter techniques confirmed that the protein cor-
responded to RhoGDI(59–204), with two extra methionine residues at
the N terminus. 
Full-length RhoGDI was expressed in the expression vector pET11d
(Pharmacia) in E. coli BL21 (DE3). The protein was initially purified on
a Q Sepharose anion exchange column, eluting with a linear gradient of
0–1 M NaCl in 20 mM Tris-chloride pH 6.3. Further purification was
achieved by a second ion-exchange step (Pharmacia MonoQ 10/10
column, linear gradient of 0–1 M NaCl in 20 mM Tris-chloride pH 8.3)
followed by size-exclusion chromatography (Pharmacia Superdex
75 column, 100 mM NaCl, 20 mM Tris-chloride pH 8.3). The resulting
protein was > 95% pure as judged by SDS–PAGE. The cDNAs coding
for mutants of RhoGDI were prepared by site-directed mutagenesis
using the polymerase chain reaction (PCR) with appropriate ‘muta-
genic’ primers; these cDNAs were subcloned into pET11d and the
protein expressed and purified as described above.
Recombinant Rac-1 was expressed in the expression vector pET11a
(Pharmacia) in E. coli B834 (DE3). The protein was purified using an
SP Sepharose cation exchange column; the protein was eluted with a
linear gradient of 0–1 M NaCl in buffer B (20 mM sodium phosphate,
5mM magnesium sulphate, 10 mM DTT pH 7.4). Two peaks were
eluted, at concentrations of 250 and 350 mM NaCl, corresponding
respectively to truncated (1–188) and full-length Rac-1. A subsequent
size-exclusion chromatography step (Pharmacia Superdex 75 column
using 100 mM NaCl in buffer B) yielded > 95% pure protein. 
NMR samples of RhoGDI were prepared in 50 mM sodium phosphate
buffer pH 6.3 (90% H2O, 10% 2H2O), 1 mM DTT, 1 mM EDTA to final
concentrations of between 0.5 mM and 0.8 mM. Samples of Rac-1
(GDP form) were prepared in the same buffer with the addition of
5 mM MgCl2. N-acetyl S-farnesyl cysteine (Calbiochem) was dissolved
in [2H6]-ethanol to a concentration of 35 mM; additions to the RhoGDI
sample were made in 1 µl aliquots. 
NMR spectra were acquired using a Bruker DMX500 or DRX600
spectrometer at a sample temperature of 25°C for the truncated
RhoGDI(59–204) and 15°C for the full-length protein. A lower temper-
ature was used for the second sample in order to reduce the rate of
proteolysis of the full-length protein. The complete assignment of the
backbone 1H, 13C, 15N resonances of RhoGDI(59–204) at 0.5 mM
was made using the HNCO, HN(CA)CO, HNCA, HN(CO)CA,
CBCANH and CBCA(CO)NH experiments, whereas similar assign-
ments of the backbone resonances of full-length RhoGDI at 0.8 mM
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were carried out using the HNCO, HN(CA)CO, CBCANH and
CBCA(CO)NH experiments. All these experiments were carried out in
the gradient-enhanced sensitivity-enhanced mode. Processing of the
three-dimensional triple-resonance data was carried out using Felix 95
software (Biosym Inc.). A semi-automated assignment strategy was
employed using an in-house programme based on simulated annealing.
[15N–1H]-TROSY spectra were recorded, using a gradient-enhanced
and sensitivity-enhanced sequence [31], on a sample of 0.25 mM
[2H,15N]-labelled RhoGDI with or without unlabelled Rac-1 at 15°C. To
assess the solvent accessibility of residues of RhoGDI in the complex,
microlitre aliquots of a stock solution of TEMPO (Sigma Chemical Co.)
were titrated into the sample of the complex to give a final concentra-
tion of ~10 mM. 1H chemical shifts are expressed relative to the methyl
resonance of sodium 2,2-dimethyl-2-silapentane-5-sulphonate (DSS) at
0 ppm. The 13C and 15N chemical shifts were indirectly referenced to
external DSS. Minimum chemical-shift changes of the amide reso-
nances of RhoGDI-1 on binding Rac-1 were estimated as follows. The
distances, in terms of 1H and 15N chemical-shifts ∆H and ∆N, from
each cross-peak in the 1H–15N HSQC spectrum of the free protein to
the nearest cross-peak in the complex were measured. The minimum
chemical-shift difference was then expressed as:
(1)
Values of this quantity of greater than 1.75 were considered significant. 
The binding of Rac-1 to wild-type and mutant RhoGDI-1 was deter-
mined by measuring the decrease in the fluorescence of mantGDP
(Molecular Probes Inc.) bound to Rac-1 on addition of RhoGDI, as
described [32].
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